ubidecarenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists 4607 303-98-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • neuquinon
  • ubidecarenone
  • Vitamin Q
prevents hemorrhagic state
  • Molecular weight: 863.37
  • Formula: C59H90O4
  • CLOGP: 12
  • LIPINSKI: 2
  • HAC: 4
  • HDO: 0
  • TPSA: 52.60
  • ALOGS: -6.65
  • ROTB: 31

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KIT,MAP2K6,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 62
kinase-selectivity-class GRK2,STK33,TEK 3
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Muscle spasticity 451.80 13.03 210 24002 35112 90569123
Ear pain 405.28 13.03 229 23983 57473 90546762
Body temperature increased 404.79 13.03 210 24002 44500 90559735
Respiratory disorder 339.67 13.03 213 23999 64603 90539632
Night sweats 227.07 13.03 222 23990 128544 90475691
Vaginal flatulence 202.45 13.03 88 24124 12550 90591685
Back pain 187.10 13.03 317 23895 316858 90287377
Proctitis 186.57 13.03 88 24124 15171 90589064
Female genital tract fistula 176.29 13.03 89 24123 17779 90586456
Radiculopathy 176.25 13.03 90 24122 18415 90585820
Vaginal discharge 174.81 13.03 91 24121 19373 90584862
Chronic sinusitis 157.66 13.03 91 24121 23711 90580524
Insomnia 146.98 13.03 294 23918 333180 90271055
Paraesthesia oral 136.18 13.03 92 24120 31567 90572668
Sinusitis 135.34 13.03 289 23923 342799 90261436
Oral candidiasis 131.35 13.03 94 24118 35361 90568874
Procedural pain 129.48 13.03 91 24121 33269 90570966
Peripheral swelling 122.40 13.03 311 23901 412795 90191440
Macular degeneration 121.13 13.03 92 24120 37878 90566357
Asthenia 114.18 13.03 357 23855 533394 90070841
Headache 105.40 13.03 482 23730 862264 89741971
Urticaria 104.84 13.03 247 23965 312487 90291748
Lower respiratory tract infection 98.56 13.03 211 24001 250448 90353787
Pruritus 92.56 13.03 336 23876 541189 90063046
Frequent bowel movements 90.72 13.03 93 24119 56842 90547393
Abdominal pain upper 82.82 13.03 235 23977 332439 90271796
Colitis ulcerative 81.10 13.03 90 24122 60176 90544059
Colitis 78.29 13.03 95 24117 69847 90534388
Haematochezia 72.44 13.03 92 24120 70821 90533414
Pain 70.15 13.03 480 23732 995861 89608374
Diarrhoea 68.81 13.03 457 23755 938733 89665502
Constipation 67.73 13.03 196 24016 280199 90324036
Rectal haemorrhage 65.73 13.03 95 24117 82649 90521586
Hepatic necrosis 60.38 13.03 31 24181 6407 90597828
General physical health deterioration 60.32 13.03 11 24201 355104 90249131
Toxicity to various agents 55.70 13.03 6 24206 287840 90316395
Maternal exposure during pregnancy 55.35 13.03 14 24198 360049 90244186
Hand deformity 46.56 13.03 11 24201 296351 90307884
Joint swelling 46.24 13.03 260 23952 503040 90101195
Glossodynia 44.88 13.03 15 24197 321764 90282471
Erythema 44.88 13.03 149 24063 229097 90375138
Exposure during pregnancy 43.59 13.03 6 24206 238404 90365831
Treatment failure 42.68 13.03 14 24198 303914 90300321
Hepatic encephalopathy 40.91 13.03 32 24180 13740 90590495
Rash 39.98 13.03 355 23857 795745 89808490
Dyspepsia 39.85 13.03 130 24082 198030 90406205
Systemic lupus erythematosus 39.35 13.03 24 24188 361872 90242363
Pemphigus 37.94 13.03 20 24192 326844 90277391
C-reactive protein increased 37.16 13.03 3 24209 181386 90422849
Duodenal ulcer perforation 35.17 13.03 8 24204 221280 90382955
Condition aggravated 33.47 13.03 68 24144 595477 90008758
Wound 33.06 13.03 20 24192 302960 90301275
Acute kidney injury 32.45 13.03 23 24189 320364 90283871
Weight decreased 29.54 13.03 188 24024 379722 90224513
Type 2 diabetes mellitus 29.17 13.03 9 24203 203235 90401000
Abdominal pain 29.05 13.03 193 24019 395528 90208707
Completed suicide 28.10 13.03 3 24209 145055 90459180
Pericarditis 27.87 13.03 19 24193 270132 90334103
Rheumatoid factor positive 27.69 13.03 6 24206 171644 90432591
Incorrect route of product administration 27.63 13.03 49 24163 50577 90553658
Therapeutic product effect incomplete 26.24 13.03 112 24100 193784 90410451
Rheumatic fever 25.43 13.03 5 24207 153116 90451119
COVID-19 25.10 13.03 7 24205 168836 90435399
Discomfort 24.87 13.03 22 24190 274313 90329922
Injury 24.52 13.03 11 24201 197338 90406897
Liver injury 23.68 13.03 8 24204 170559 90433676
Full blood count decreased 23.43 13.03 34 24178 29655 90574580
Death 23.26 13.03 55 24157 456496 90147739
Anti-cyclic citrullinated peptide antibody positive 22.61 13.03 18 24194 236415 90367820
Fatigue 22.36 13.03 432 23780 1153591 89450644
Drug intolerance 21.95 13.03 55 24157 447536 90156699
Synovitis 21.79 13.03 34 24178 329718 90274517
Rheumatoid arthritis 19.84 13.03 42 24170 362572 90241663
C-reactive protein abnormal 19.47 13.03 5 24207 127424 90476811
Calcitonin secretion disorder 19.15 13.03 4 24208 42 90604193
Hypertension 18.91 13.03 61 24151 457471 90146764
Helicobacter infection 18.47 13.03 20 24192 226830 90377405
Hypokalaemia 18.46 13.03 6 24206 131110 90473125
Product use in unapproved indication 18.34 13.03 39 24173 336197 90268038
Fibromyalgia 18.14 13.03 17 24195 206252 90397983
Vomiting 18.00 13.03 303 23909 787990 89816245
Overdose 17.77 13.03 10 24202 157699 90446536
Mitochondrial DNA deletion 17.29 13.03 3 24209 10 90604225
Arthropathy 17.18 13.03 46 24166 366196 90238039
Febrile neutropenia 16.51 13.03 11 24201 158338 90445897
Hepatic enzyme increased 16.41 13.03 46 24166 360690 90243545
Thrombocytopenia 16.33 13.03 19 24193 208706 90395529
Low density lipoprotein increased 16.23 13.03 15 24197 8070 90596165
Hepatotoxicity 16.17 13.03 37 24175 45805 90558430
Swollen joint count increased 15.81 13.03 5 24207 111201 90493034
Cataract operation 15.51 13.03 13 24199 6150 90598085
Ureteral stent insertion 15.46 13.03 5 24207 313 90603922
Lip dry 15.35 13.03 4 24208 100951 90503284
Wheezing 15.29 13.03 25 24187 238055 90366180
Pneumonia 15.17 13.03 104 24108 637955 89966280
Myalgia 15.06 13.03 89 24123 175036 90429199
Pulmonary fibrosis 14.99 13.03 5 24207 107498 90496737
Joint range of motion decreased 14.72 13.03 9 24203 135634 90468601
Pyrexia 14.38 13.03 252 23960 660233 89944002
Salpingo-oophorectomy 14.38 13.03 4 24208 149 90604086
Breast prosthesis user 14.38 13.03 4 24208 149 90604086
Anaphylactic reaction 14.23 13.03 3 24209 87521 90516714
Neutropenia 14.09 13.03 24 24188 224880 90379355
Bursitis 13.92 13.03 9 24203 131645 90472590
Intentional overdose 13.74 13.03 4 24208 93830 90510405
Alopecia 13.67 13.03 77 24135 494994 90109241
Breast cancer stage III 13.52 13.03 3 24209 84444 90519791
Feeling abnormal 13.12 13.03 83 24129 167152 90437083
Wound infection 13.10 13.03 6 24206 106396 90497839

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fatigue 80.47 15.76 230 8361 435411 42177333
Blindness cortical 40.86 15.76 11 8580 483 42612261
Asthenia 35.86 15.76 131 8460 280662 42332082
Full blood count decreased 25.92 15.76 26 8565 20534 42592210
Dizziness 23.56 15.76 106 8485 249148 42363596
Dysgeusia 22.54 15.76 31 8560 34158 42578586
Constipation 20.89 15.76 76 8515 162215 42450529
Protein total increased 20.10 15.76 10 8581 2568 42610176
Plasma cell myeloma 19.94 15.76 35 8556 47543 42565201
Diarrhoea 19.61 15.76 159 8432 460690 42152054
Toxicity to various agents 19.48 15.76 11 8580 229125 42383619
Abdominal discomfort 19.16 15.76 45 8546 75210 42537534
Myalgia 18.79 15.76 52 8539 96028 42516716
Tendon calcification 18.17 15.76 4 8587 74 42612670
Peripheral swelling 17.79 15.76 49 8542 90221 42522523
Muscle spasms 17.25 15.76 47 8544 85997 42526747
Application site inflammation 17.18 15.76 4 8587 96 42612648
Back pain 17.07 15.76 65 8526 141711 42471033
Feeling abnormal 15.91 15.76 40 8551 69746 42542998

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vaginal flatulence 215.13 12.71 87 25342 12057 110551813
Muscle spasticity 193.73 12.71 114 25315 35801 110528069
Female genital tract fistula 192.50 12.71 88 25341 16431 110547439
Ear pain 192.06 12.71 131 25298 53095 110510775
Vaginal discharge 191.87 12.71 90 25339 17818 110546052
Proctitis 190.45 12.71 88 25341 16839 110547031
Radiculopathy 182.28 12.71 89 25340 19247 110544623
Macular degeneration 175.61 12.71 90 25339 21569 110542301
Chronic sinusitis 165.94 12.71 91 25338 24993 110538877
Body temperature increased 152.26 12.71 115 25314 54598 110509272
Paraesthesia oral 148.57 12.71 94 25335 33577 110530293
Procedural pain 134.16 12.71 90 25339 35475 110528395
Oral candidiasis 131.04 12.71 97 25332 44663 110519207
Respiratory disorder 125.49 12.71 115 25314 71267 110492603
Back pain 101.42 12.71 247 25182 370749 110193121
Night sweats 89.62 12.71 131 25298 133852 110430018
Frequent bowel movements 83.10 12.71 92 25337 71298 110492572
Colitis ulcerative 75.43 12.71 91 25338 77272 110486598
Headache 73.13 12.71 397 25032 881980 109681890
Colitis 69.80 12.71 101 25328 102222 110461648
Insomnia 68.39 12.71 210 25219 360380 110203490
Dyspepsia 64.11 12.71 138 25291 190827 110373043
Toxicity to various agents 63.76 12.71 16 25413 480539 110083331
Constipation 62.91 12.71 203 25226 357583 110206287
Peripheral swelling 62.01 12.71 219 25210 403815 110160055
Pain 61.96 12.71 403 25026 954552 109609318
Rectal haemorrhage 61.81 12.71 104 25325 119729 110444141
Asthenia 61.80 12.71 317 25112 688682 109875188
Haematochezia 59.23 12.71 100 25329 115424 110448446
General physical health deterioration 56.72 12.71 14 25415 425281 110138589
Hepatic necrosis 54.81 12.71 32 25397 9890 110553980
Sinusitis 51.82 12.71 168 25261 296520 110267350
Fatigue 44.33 12.71 450 24979 1215508 109348362
Weight decreased 43.03 12.71 217 25212 467840 110096030
Erythema 42.14 12.71 155 25274 291292 110272578
Diarrhoea 39.74 12.71 418 25011 1139087 109424783
COVID-19 39.29 12.71 5 25424 245055 110318815
Completed suicide 34.26 12.71 7 25422 242374 110321496
Pruritus 33.73 12.71 239 25190 581321 109982549
Acute kidney injury 31.97 12.71 61 25368 635369 109928501
C-reactive protein increased 31.41 12.71 6 25423 217913 110345957
Myalgia 31.06 12.71 117 25312 222264 110341606
Overdose 30.56 12.71 8 25421 233786 110330084
Blindness cortical 30.42 12.71 11 25418 1124 110562746
Abdominal pain upper 30.07 12.71 159 25270 348952 110214918
Drug abuse 29.99 12.71 3 25426 177408 110386462
Urticaria 28.68 12.71 147 25282 318710 110245160
Treatment failure 27.09 12.71 15 25414 277219 110286651
Lower respiratory tract infection 26.89 12.71 119 25310 242987 110320883
Therapeutic product effect incomplete 26.63 12.71 112 25317 223693 110340177
Hepatic encephalopathy 25.53 12.71 32 25397 28224 110535646
Feeling abnormal 25.17 12.71 95 25334 180616 110383254
Maternal exposure during pregnancy 24.60 12.71 14 25415 254869 110309001
Abdominal pain 23.16 12.71 199 25230 512790 110051080
Hand deformity 22.57 12.71 11 25418 218495 110345375
Exposure during pregnancy 21.37 12.71 6 25423 167418 110396452
Full blood count decreased 20.88 12.71 31 25398 32068 110531802
Product use in unapproved indication 20.73 12.71 45 25384 447332 110116538
Febrile neutropenia 20.10 12.71 26 25403 316741 110247129
Duodenal ulcer perforation 19.84 12.71 8 25421 177692 110386178
Calcitonin secretion disorder 19.75 12.71 4 25425 42 110563828
Incorrect route of product administration 18.90 12.71 44 25385 64017 110499853
Dysgeusia 18.42 12.71 46 25383 69939 110493931
Hyponatraemia 18.24 12.71 14 25415 217639 110346231
Coma 17.51 12.71 3 25426 117866 110446004
Mitochondrial DNA deletion 17.31 12.71 3 25426 12 110563858
Thrombocytopenia 17.08 12.71 34 25395 348851 110215019
Malaise 16.95 12.71 232 25197 671587 109892283
Low density lipoprotein increased 16.46 12.71 16 25413 10650 110553220
Intentional overdose 16.44 12.71 5 25424 132496 110431374
Wound 16.19 12.71 18 25411 234419 110329451
Condition aggravated 16.09 12.71 101 25328 734735 109829135
C-reactive protein abnormal 15.91 12.71 5 25424 129690 110434180
Rash 15.89 12.71 271 25158 820693 109743177
Glossodynia 15.38 12.71 17 25412 221987 110341883
Systemic lupus erythematosus 15 12.71 22 25407 254316 110309554
Hypokalaemia 14.95 12.71 12 25417 182436 110381434
Drug intolerance 14.90 12.71 46 25383 406466 110157404
Rheumatoid factor positive 14.57 12.71 6 25423 131634 110432236
Rheumatic fever 14.55 12.71 5 25424 122574 110441296
Flatulence 14.49 12.71 35 25394 52114 110511756
Asthma 14.42 12.71 22 25407 250269 110313601
Joint swelling 14.20 12.71 160 25269 442685 110121185
Epilepsy 13.93 12.71 3 25426 100206 110463664
Tendon calcification 13.91 12.71 4 25425 196 110563674
Blood citric acid increased 13.26 12.71 3 25426 55 110563815
White blood cell count decreased 13.09 12.71 94 25335 229296 110334574
Hepatotoxicity 13.00 12.71 38 25391 63362 110500508
Multiple lentigines syndrome 12.93 12.71 4 25425 252 110563618
Type 2 diabetes mellitus 12.92 12.71 13 25416 177219 110386651

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01EB09 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
OTHER CARDIAC PREPARATIONS
Other cardiac preparations
CHEBI has role CHEBI:22586 antioxidants
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:173084 ferroptosis inhibitors

Related Drugs by ATC class:

C01EB Other cardiac preparations 15 drugs
acadesineacoramidisadenosinecamphorcreatinolfosfateibuprofenindomethacinivabradinemavacamtenmeldoniumphosphocreatineranolazine show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Congestive heart failure indication 42343007 DOID:6000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01065 KEGG_DRUG
4021303 VUID
N0000148739 NUI
4021303 VANDF
CHEBI:46245 CHEBI
CHEMBL454801 ChEMBL_ID
C010524 MESH_SUPPLEMENTAL_RECORD_UI
3463 INN_ID
DB09270 DRUGBANK_ID
EJ27X76M46 UNII
21406 RXNORM
15490 MMSL
194138 MMSL
233517 MMSL
270084 MMSL
33141 MMSL
33199 MMSL
33200 MMSL
365406 MMSL
37841 MMSL
392855 MMSL
393081 MMSL
41597 MMSL
46285 MMSL
74202 MMSL
d04523 MMSL
003911 NDDF
012958 NDDF
412129003 SNOMEDCT_US
412130008 SNOMEDCT_US
C0041536 UMLSCUI
U10 PDB_CHEM_ID
5281915 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
IQQU Acne Serum HUMAN OTC DRUG LABEL 3 50403-226 LOTION 0.00 g TOPICAL UNAPPROVED DRUG OTHER 9 sections
Vita-Rx Diabetic Vitamin HUMAN PRESCRIPTION DRUG LABEL 14 69677-050 CAPSULE, GELATIN COATED 50 mg ORAL unapproved drug other 5 sections
Zyrexal HUMAN PRESCRIPTION DRUG LABEL 8 72380-915 TABLET 75 mg ORAL unapproved drug other 8 sections
Virexa HUMAN PRESCRIPTION DRUG LABEL 8 85477-606 TABLET 50 mg ORAL unapproved drug other 5 sections
YVES CONOPEPTIDE LUXURY TIGHTEN CREME EYE MASK HUMAN OTC DRUG LABEL 4 85779-002 CREAM 0.02 g TOPICAL unapproved drug other 8 sections